摘要
门脉系统血栓(PVST)是开腹或腹腔镜下脾切除或联合断流术后常见的并发症,可能会危害术后患者的健康,严重时甚至会危及患者生命。肝硬化门脉高压患者术后PVST的形成和发展受很多因素的影响,抗凝药物的正确使用在预防和治疗PVST中起至关重要的作用。本文通过探讨抗凝药物在防治开腹或腹腔镜下脾切除或联合断流术术后PVST的研究进展,阐述现有抗凝药物的抗凝特性和抗凝治疗方案,进一步指导临床抗凝药物的使用,降低PVST的发生率,改善此类手术患者的生存质量。
Portal vein system thrombosis (PVST) is a common complication in patients after open or laparoscopic splenectomy or combined with devascularization. It may endanger the health of the patients after surgery and even potentially endanger the patient's life in severe cases. The formation and development of PVST is affected by many factors, and the correct use of anticoagulant drugs play a vital role in the prevention and treatment of PVST in postoperative patients with cirrhotic portal hypertension. This article discusses the advances in research on the prevention and treatment of PVST after open or laparoscopic splenectomy or combined with devascularization with anticoagulant drugs, and reviews the current anticoagulant properties and recommends of anticoagulant therapy, further guides the use of clinical anticoagulant drugs to reduce the incidence of PVST and improve the quality of life in patients with such surgery.
作者
周保换
蒋国庆
Zhou Baohuan;Jiang Guoqing(Dalian Medical University,Dalian 116044,China;Department of Hepatobiliary Surgery,Clinical Medical College of Yangzhou University,Yaagzhou 225001,China)
出处
《国际外科学杂志》
2019年第2期131-136,共6页
International Journal of Surgery
关键词
门脉系统
血栓栓塞
肝硬化
脾切除术
抗凝药物
Portal system
Thromboembolism
Liver cirrhosis
Splenectomy
Anticoagulants
